Summary

Eligibility
for people ages 10-12 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UC Davis
Dates
study started
completion around
Principal Investigator
by Julie HT Dang, PhD (ucdavis)

Description

Summary

Develop, implement, and evaluate a culturally tailored multilevel intervention to increase uptake of the HPV vaccine among eligible patients ages 10-12 of the University of California, Davis Health Community Physician (UCDH CP) primary care practices using a randomized controlled trial design.

Official Title

Human Papillomavirus Ends Here: A Multilevel Intervention to Increase Uptake of the HPV Vaccine Among Adolescents

Details

The goal of this study is to use an evidence-based approach to develop, implement and evaluate a ML intervention on increasing HPV vaccine uptake among UCDH CP patients ages 10-12.

Aim 1. Refine and finalize a parent, primary care team and clinic ML intervention to increase uptake and completion of the HPV vaccine series among adolescent patients of the UCDH CP practices. In Phase 1, semi-structured qualitative interviews with key stakeholders will be conducted to refine the content and implementation approaches.

Aim 2. Conduct and evaluate the effectiveness and sustainability of the ML intervention. In Phase 2, twelve UCDH CP practices will be recruited to participate in a 2-arm parallel group randomized controlled trial. The primary outcome age-appropriate completion of the HPV vaccine series will be assessed via Epic, the UCDHS electronic medical record (EMR) software. We hypothesize that patients of clinics in the intervention condition will have significantly higher HPV completion rates compared to patients of clinics in the control condition (usual care).

Keywords

HPV Vaccine, HPV, Human Papillomavirus, Intervention Arm

Eligibility

You can join if…

Open to people ages 10-12

• Clinic patients between the ages of 10-12 who are eligible for the HPV vaccine

You CAN'T join if...

• Clinic patients who already received the HPV vaccine or with any contraindication to the HPV vaccine.

Location

  • University of California Davis Health
    Sacramento California 95817 United States

Lead Scientist at University of California Health

  • Julie HT Dang, PhD (ucdavis)
    Assistant Adjunct Professor, Med: Public Health Sciences, School of Medicine. Authored (or co-authored) 26 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
ID
NCT06831929
Study Type
Interventional
Participants
Expecting 2232 study participants
Last Updated